P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000970496.55340.69 |
| _version_ | 1827331413886631936 |
|---|---|
| author | Raija Silvennoinen Anu Partanen Anders Waage Valdas Pečeliūnas Fredrik Schjesvold Pekka Anttila Katarina Uttervall Marjaana Säily Mervi Putkonen Kristina Carlson Einar Haukas Marja Sankelo Damian Szatkowski Markus Hansson Anu Marttila Per Axelsson Ronald Svensson Birgitta Lauri Maija Mikkola Conny Karlsson Johanna Abelsson Erik Ahlstrand Anu Sikiö Monika Klimkowska Reda Matuzeviciene Mona Hoyseter Fenstad Sorella Ilveskero Hareth Nahi |
| author_facet | Raija Silvennoinen Anu Partanen Anders Waage Valdas Pečeliūnas Fredrik Schjesvold Pekka Anttila Katarina Uttervall Marjaana Säily Mervi Putkonen Kristina Carlson Einar Haukas Marja Sankelo Damian Szatkowski Markus Hansson Anu Marttila Per Axelsson Ronald Svensson Birgitta Lauri Maija Mikkola Conny Karlsson Johanna Abelsson Erik Ahlstrand Anu Sikiö Monika Klimkowska Reda Matuzeviciene Mona Hoyseter Fenstad Sorella Ilveskero Hareth Nahi |
| author_sort | Raija Silvennoinen |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:35:53Z |
| format | Article |
| id | doaj.art-d72831d2759849ac8fefd808f7e030d6 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:35:53Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-d72831d2759849ac8fefd808f7e030d62024-03-03T09:43:37ZengWileyHemaSphere2572-92412023-08-017e553406910.1097/01.HS9.0000970496.55340.69202308003-00798P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTSRaija Silvennoinen0Anu Partanen1Anders Waage2Valdas Pečeliūnas3Fredrik Schjesvold4Pekka Anttila5Katarina Uttervall6Marjaana Säily7Mervi Putkonen8Kristina Carlson9Einar Haukas10Marja Sankelo11Damian Szatkowski12Markus Hansson13Anu Marttila14Per Axelsson15Ronald Svensson16Birgitta Lauri17Maija Mikkola18Conny Karlsson19Johanna Abelsson20Erik Ahlstrand21Anu Sikiö22Monika Klimkowska23Reda Matuzeviciene24Mona Hoyseter Fenstad25Sorella Ilveskero26Hareth Nahi271 Helsinki University Hospital Cancer Center, Hematology, Helsinki, Finland3 Kuopio University Hospital, Hematology, Kuopio, Finland4 St. Olav’s University Hospital, Norway5 Vilnius university hospital Santaros klinikos, Vilnius, Lithuania6 Oslo Myeloma Center, Oslo, Norway1 Helsinki University Hospital Cancer Center, Hematology, Helsinki, Finland7 Huddinge Hospital, Stockholm, Sweden8 Oulu University Hospital, Hematology, Oulu, Finland9 Turku University Hospital, Hematology, Turku, Finland10 Uppsala University Hospital, Hematology, Uppsala, Sweden11 Stavanger University Hospital, Hematology, Stavanger, Norway12 Tampere University Hospital, Hematology, Tampere, Finland13 Förde Central Hospital, Förde, Norway14 Skåne University Hospital, Skåne, Sweden15 Kymenlaakso Central Hospital, Kotka, Finland16 Helsingborg Hospital, Helsingborg, Sweden17 Linköping University Hospital, Linköping, Sweden18 Sunderby Hospital, Luleå, Sweden19 Päijät-Häme Central Hospital, Lahti, Finland20 Halland Hospital, Halmstad, Sweden21 Uddevalla Hospital, Uddevalla, Sweden22 Örebro Central Hospital, Örebro, Sweden23 Central Finland Central Hospital, Jyväskylä, Finland7 Huddinge Hospital, Stockholm, Sweden24 Vilnius University Hospital, Vilnius, Lithuania25 St. Olav’s University Hospital, Trondheim, Norway26 Helsinki University Hospital, Helsinki, Finland27 Karolinska Institute, Stockholm, Swedenhttp://journals.lww.com/10.1097/01.HS9.0000970496.55340.69 |
| spellingShingle | Raija Silvennoinen Anu Partanen Anders Waage Valdas Pečeliūnas Fredrik Schjesvold Pekka Anttila Katarina Uttervall Marjaana Säily Mervi Putkonen Kristina Carlson Einar Haukas Marja Sankelo Damian Szatkowski Markus Hansson Anu Marttila Per Axelsson Ronald Svensson Birgitta Lauri Maija Mikkola Conny Karlsson Johanna Abelsson Erik Ahlstrand Anu Sikiö Monika Klimkowska Reda Matuzeviciene Mona Hoyseter Fenstad Sorella Ilveskero Hareth Nahi P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS HemaSphere |
| title | P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS |
| title_full | P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS |
| title_fullStr | P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS |
| title_full_unstemmed | P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS |
| title_short | P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS |
| title_sort | p898 a prospective phase 2 study to assess minimal residual disease after ixazomib lenalidomide dexamethasone ird treatment for newly diagnosed transplant eligible multiple myeloma patients |
| url | http://journals.lww.com/10.1097/01.HS9.0000970496.55340.69 |
| work_keys_str_mv | AT raijasilvennoinen p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients AT anupartanen p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients AT anderswaage p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients AT valdaspeceliunas p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients AT fredrikschjesvold p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients AT pekkaanttila p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients AT katarinauttervall p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients AT marjaanasaily p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients AT merviputkonen p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients AT kristinacarlson p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients AT einarhaukas p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients AT marjasankelo p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients AT damianszatkowski p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients AT markushansson p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients AT anumarttila p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients AT peraxelsson p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients AT ronaldsvensson p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients AT birgittalauri p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients AT maijamikkola p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients AT connykarlsson p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients AT johannaabelsson p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients AT erikahlstrand p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients AT anusikio p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients AT monikaklimkowska p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients AT redamatuzeviciene p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients AT monahoyseterfenstad p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients AT sorellailveskero p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients AT harethnahi p898aprospectivephase2studytoassessminimalresidualdiseaseafterixazomiblenalidomidedexamethasoneirdtreatmentfornewlydiagnosedtransplanteligiblemultiplemyelomapatients |